Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Internal Medicine
•
Chronic kidney disease
•
Nephrology
•
Endocrinology
Do you recommend stopping a SGLT2i indefinitely if a patient with chronic kidney disease and diabetes develops euglycemic diabetic ketoacidosis?
Answer from: at Academic Institution
I would. In my opinion, the risk of ketoacidosis will outweigh the possible benefit from SGLTs.
Comments
at CommonSpirit
Absolutely, I would stop SGLT as one episode shoul...
at Atrium Health Wake Forest Baptist Medical Center
I would, depending on the individual patient with ...
12214
12216
Sign in or Register to read more
22632
Related Questions
Is there a role for monitoring PTH levels in patients with advanced chronic kidney disease who are receiving denosumab to assess for adynamic bone disease?
How do you approach managing patients with diabetic kidney disease and proteinuria who develop hypoglycemia after initiation of a SGLT2 inhibitor?
Are recurrent UTIs a contraindication to SGLT2i use?
Would you stop denosumab in a patient with chronic kidney disease if they develop asymptomatic hypocalcemia after the injection?
Would you recommend switching a diabetic CKD patient on oral semaglutide to the subcutaneous form since the benefits in CKD have primarily been reported in studies using subcutaneous GLP-1 receptor agonists?
What is the optimal number of days to hold apixaban prior to a kidney biopsy or tunneled dialysis catheter placement?
Are there instances when you recommend initiation of dialysis in patients with advanced chronic kidney disease who are scheduled for a major surgery but do not currently have any indications for renal replacement therapy?
Do you check EPO levels in patients with anemia of chronic kidney disease?
For patients with eGFR around 30, do you still consider using reclast or evenity at adjusted doses?
Is the phosphorus-lowering benefit of patiromer compelling enough to switch a patient with chronic hyperkalemia and hyperphosphatemia from sodium zirconium cyclosilicate to patiromer?
Absolutely, I would stop SGLT as one episode shoul...
I would, depending on the individual patient with ...